Literature DB >> 7818962

Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt.

I Adatia1, S E Barrow, P D Stratton, J M Ritter, S G Haworth.   

Abstract

OBJECTIVE: To investigate the effect of intracardiac repair on the abnormal biosynthesis of prostacyclin (PGI2) and thromboxane A2 (TXA2) in children with congenital heart disease and increased pulmonary blood flow.
DESIGN: A prospective study with immunoaffinity chromatography and gas chromatography-mass spectrometry to measure the urinary excretion products of PGI2 (2,3-dinor-6-oxo-prostaglandin (PG) F1 alpha (2,3-dinor-6-oxo-PGF1 alpha)) and TXA2 (2,3-dinor-TXB2) before operation, in the first 12-24 h after operation, and at discharge from hospital.
SETTING: A supraregional referral centre for patients with congenital heart disease. PATIENTS: 15 patients aged 2 to 60 months (median 7 months) with a left to right shunt who underwent intracardiac repair.
RESULTS: The preoperative 2,3-dinor-TXB2 excretion rate was greater than that found previously in a control group of 16 healthy children with a median (range) age of 24 (6-36) months (1159(201) v 592(122) ng/g creatinine in controls, P = 0.006). The excretion rate rose after operation to 9600(3832) ng/g creatinine (P = 0.01) and decreased before discharge to 1071(191) ng/g creatinine (NS), but remained greater than that of the control group (P = 0.014). Before operation 2,3-dinor-6-oxo-PGF1 alpha excretion rates were similar to those of the healthy children (482(68) v 589(95) ng/g creatinine in controls) but increased after operation to 19,668(11,162) ng/creatinine (P = 0.002) and fell at discharge to 1621(245) ng/g creatinine although this was higher than both preoperative and control rates (P = 0.005 and P = 0.0002 respectively). The preoperative ratio of 2,3-dinor-TXB2 to 2,3-dinor-6-oxo-PGF1 alpha excretion was greater than that of the control group (3.2(0.8) v 1.3(0.22) in controls, (P = 0.005)), decreased significantly after operation to 0.9(0.13) (P = 0.016), and changed little, to 0.7(0.12), before discharge. The last two ratios were similar to those in normal children and significantly lower than those before operation (P = 0.004).
CONCLUSION: In children with a left to right shunt the ratio of the excretion rates of the metabolites of TXA2 and PGI2 was abnormal before operation, which favoured vasoconstriction and platelet aggregation, but had decreased at discharge from hospital. The increase in excretion of PGI2 metabolites over TXA2 metabolite after intracardiac repair augurs well for pulmonary vascular recovery.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7818962      PMCID: PMC1025613          DOI: 10.1136/hrt.72.5.452

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  34 in total

1.  Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls.

Authors:  S Moncada; J R Vane
Journal:  N Engl J Med       Date:  1979-05-17       Impact factor: 91.245

2.  Pulmonary injury secondary to extracorporeal circulation. An ultrastructural study.

Authors:  N B Ratliff; W G Young; D B Hackel; E Mikat; J W Wilson
Journal:  J Thorac Cardiovasc Surg       Date:  1973-03       Impact factor: 5.209

3.  Prostacyclin administration during cardiopulmonary bypass in man.

Authors:  D B Longmore; J G Bennett; P M Hoyle; M A Smith; A Gregory; T Osivand; W A Jones
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

4.  Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins.

Authors:  D E Chenoweth; S W Cooper; T E Hugli; R W Stewart; E H Blackstone; J W Kirklin
Journal:  N Engl J Med       Date:  1981-02-26       Impact factor: 91.245

5.  Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium.

Authors:  E A Higgs; S Moncada; J R Vane; J P Caen; H Michel; G Tobelem
Journal:  Prostaglandins       Date:  1978-07

6.  Contribution of variable entrance and exit block in protected foci to arrhythmogenesis in isolated ventricular tissues.

Authors:  J E Rosenthal; G R Ferrier
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

7.  Prevention of complement-induced pulmonary hypertension and improvement of right ventricular function by selective thromboxane receptor antagonism.

Authors:  W J Smith; M P Murphy; R F Appleyard; R J Rizzo; L Aklog; R G Laurence; L H Cohn
Journal:  J Thorac Cardiovasc Surg       Date:  1994-03       Impact factor: 5.209

8.  Evidence for a direct stimulatory effect of prostacyclin on renin release in man.

Authors:  C Patrono; F Pugliese; G Ciabattoni; P Patrignani; A Maseri; S Chierchia; B A Peskar; G A Cinotti; B M Simonetti; A Pierucci
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

9.  Prostacyclin in cardiopulmonary bypass operations.

Authors:  A Faichney; K G Davidson; D J Wheatley; J F Davidson; I D Walker
Journal:  J Thorac Cardiovasc Surg       Date:  1982-10       Impact factor: 5.209

10.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

Authors:  M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

View more
  4 in total

Review 1.  Surgical strategies for patients with congenital heart disease and severe pulmonary hypertension in low/middle-income countries.

Authors:  Sachin Talwar; Vikas Kumar Keshri; Shiv Kumar Choudhary; Saurabh Kumar Gupta; Sivasubramanian Ramakrishnan; Rajnish Juneja; Anita Saxena; Shyam Sunder Kothari; Balram Airan
Journal:  Heart Asia       Date:  2015-10-09

Review 2.  Pulmonary Hypertension.

Authors:  Peter Oishi; Jeffrey R Fineman
Journal:  Pediatr Crit Care Med       Date:  2016-08       Impact factor: 3.624

3.  Platelets in pulmonary hypertension: a causative role or a simple association?

Authors:  Keyhan Sayadpour Zanjani
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

Review 4.  Treatment of pediatric pulmonary hypertension.

Authors:  Amy Hawkins; Robert Tulloh
Journal:  Vasc Health Risk Manag       Date:  2009-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.